Home Other Building Blocks 1020172-07-9
1020172-07-9,MFCD19443646
Catalog No.:AA000692

1020172-07-9 | Dcc-2036

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$15.00   $10.00
- +
5mg
98%
in stock  
$36.00   $26.00
- +
10mg
98%
in stock  
$54.00   $38.00
- +
50mg
98%
in stock  
$152.00   $107.00
- +
1g
98%
in stock  
$2,331.00   $1,632.00
- +
  • Technical Information
  • Properties
  • Upstream Synthesis Route
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Upstream Synthesis Route
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA000692
Chemical Name:
Dcc-2036
CAS Number:
1020172-07-9
Molecular Formula:
C30H28FN7O3
Molecular Weight:
553.5868
MDL Number:
MFCD19443646
SMILES:
CNC(=O)c1nccc(c1)Oc1ccc(c(c1)F)NC(=O)Nc1cc(nn1c1ccc2c(c1)cccn2)C(C)(C)C
Properties
Computed Properties
 
Complexity:
904  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
41  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
7  
XLogP3:
4.9  

Upstream Synthesis Route

[1]Patent:US2008/90856,2008,A1,.Locationinpatent:Page/Pagecolumn49

[2]Patent:WO2013/36232,2013,A2,.Locationinpatent:Paragraph00358

[1]Patent:WO2013/36232,2013,A2,

[1]Patent:WO2013/36232,2013,A2,

[1]Patent:WO2013/36232,2013,A2,

[1]Patent:WO2013/36232,2013,A2,

Downstream Synthesis Route

[1]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2008/90856,2008,A1Locationinpatent:Page/Pagecolumn49

[2]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-WO2013/36232,2013,A2Locationinpatent:Paragraph00358

[3]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2021/275518,2021,A1Locationinpatent:Paragraph0474

[1]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2008/90856,2008,A1Locationinpatent:Page/Pagecolumn49

[2]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-WO2013/36232,2013,A2Locationinpatent:Paragraph00358

[3]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2021/275518,2021,A1Locationinpatent:Paragraph0474

[1]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-WO2013/36232,2013,A2

[2]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2021/275518,2021,A1

[1]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-WO2013/36232,2013,A2

[2]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2021/275518,2021,A1

[1]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-WO2013/36232,2013,A2

[2]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2021/275518,2021,A1

Literature

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters 20130801

Title: Philadelphia-positive acute lymphoblastic leukemia: current treatment options.

Journal: Current oncology reports 20121001

Title: The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Journal: Blood 20111110

Title: The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

Journal: Cancer research 20110501

Title: Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.

Journal: Cancer cell 20110412

Title: Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110115

Title: Chan WW, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011, 19(4), 556-568.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1020172-07-9
Tags:1020172-07-9 Molecular Formula|1020172-07-9 MDL|1020172-07-9 SMILES|1020172-07-9 Dcc-2036